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520Vasculitis resulting from a superﬁcial femoral artery
angioplasty with a paclitaxel-eluting balloon
Shannon D. Thomas, FRACS,a Robert R. A. McDonald, FACD,b,c and Ramon L. Varcoe, MS, FRACS,a,d,e
Sydney, New South Wales, Australia
Drug-eluting balloons (DEBs) coated with the antiproliferative agent paclitaxel may improve primary patency by
reducing recurrent luminal stenosis. A proportion of the active drug and excipient coating are known to embolize distally,
but until now, there have been no reports of adverse events resulting from their use. We report an unusual case of
a painful nodular, biopsy specimen-proven vasculitic rash that afﬂicted the ipsilateral lower limb of a patient after
superﬁcial femoral artery treatment with a DEB. This adverse event may have implications for the use of DEB in this and
other vascular territories. (J Vasc Surg 2014;59:520-3.)Drug-eluting balloons (DEBs) are effective at reducing
intimal hyperplasia after angioplasty of the superﬁcial
femoral artery, infrapopliteal circulation, and arteriovenous
ﬁstulas.1-4 As a tool to both prevent and treat restenosis,
DEBs are being applied to an ever-broader variety of
vascular territories, including the carotid and coronary
arteries.5-7 Until now, there have been no reports of target
organ vasculitic, allergic, or hypersensitivity reactions with
the use of this device.
CASE REPORT
A 72-year-old woman presented to our institution with
a progressive 1-month history of severely restrictive recurrent left
leg claudication. Before presentation, her left leg had been asymp-
tomatic for 9 months after undergoing bare-metal stent revascular-
ization of the midsuperﬁcial femoral artery. Examination revealed
palpable bilateral femoral pulses but absent popliteal and pedal
pulses on the symptomatic side. Her limbs showed no evidence
of venous disease, rash, or ulceration. Arterial duplex ultrasound
imaging revealed a critical in-stent stenosis of the previously placed
superﬁcial femoral artery stent (peak systolic velocity, 438 cm/s)
with a reduced ankle-brachial pressure index of 0.75.
She had a history of dyslipidemia and hypertension, with
known allergies to rosuvastatin (skin rash) and ezetimibe (skin
rash). She was receiving lipid-lowering (gemﬁbrozil), antihyperten-
sive (ramipril), and dual-antiplatelet (clopidogrel and aspirin)
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://dx.doi.org/10.1016/j.jvs.2013.03.013The patient underwent an elective superﬁcial femoral artery
angioplasty procedure. The lesion was approached through an
atraumatic antegrade left common femoral artery puncture and
placement of a 6F Britetip sheath (Cordis, Johnson & Johnson,
Warren, NJ). After predilatation with a 6-  100-mm conventional
Fox Cross balloon catheter (Abbott Vascular, Abbott Park, Ill),
a 6-  120-mm In.Pact Admiral DEB, with paclitaxel coating
(3 mg/mm2; Invatec, Medtronic, Minn) was inﬂated according
to the manufacturer’s recommendation. Completion angiography
demonstrated a pleasing angiographic result, free of dissection,
recoil, or thrombus. No evidence of distal embolization was
apparent on runoff angiography. There were strong popliteal and
pedal pulses after the procedure, and she was discharged the
next day with no evidence of rash.
She presented 1 week after the procedure after developing
a mildly painful rash, prominent on the distal aspect of her left
lower limb from the lower thigh to the ankle but which spared
the foot (Fig 1). The rash consisted of nonblanching, small
erythematous nodules that were nonhemorrhagic. No additional
cutaneous lesions were noted on her body.
Analysis of a punch biopsy specimen showed epidermal and
upper dermal edema with an intense inﬂammation of the
medium-sized vessels in the superﬁcial subcutaneous fat. Promi-
nent ﬁbrin deposition and a mononuclear inﬁltrate within the arte-
riole walls was noted, as well as thrombosis of surrounding small
vessels and a diffuse inﬁltrate containing neutrophils and eosino-
phils (Fig 2). The result of a vasculitic blood screen was negative
for the presence of an underlying systemic vasculitis syndrome.
In view of the histopathologic analysis, the distribution of the
rash, and its temporal relationship to the procedure, a diagnosis
of vasculitis secondary to the DEB was made.
The patient was treated with a short course of oral steroids and
emulsifying ointment. During the next 12 weeks, the rash
continued to improve but did not completely resolve. Pain and
itch have since abated, and no serious adverse event has eventuated
at 4 months of follow-up.
DISCUSSION
The current commercially available DEBs all use the
antiproliferative drug paclitaxel to prevent or treat resteno-
sis after the successful dilatation of an arterial stenosis. This
Fig 1. A, Vasculitic rash conﬁned to the left leg after therapy with a paclitaxel-eluting balloon. B, Nodular,
erythematous macules in the distribution of the superﬁcial femoral artery treated with a paclitaxel-eluting balloon. C,
Magniﬁed view of the vasculitic rash on the lower leg, demonstrating nonblanching, nonhemorrhagic, nodular,
erythematous macules.
Fig 2. A, Photomicrograph (original magniﬁcation, 40) of histologic specimen demonstrates inﬂammation and ﬁbrin
within the wall of an arteriole within the subcutaneous fat (arrow). B, Photomicrograph (original magniﬁcation, 400)
shows mixed cellular inﬁltrate comprising lymphocytes, neutrophils, and eosinophils in the subcutis and a thrombosed
small vessel with ﬁbrin within its wall (arrow).
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smooth muscle cells that would otherwise accumulate
within the neointima and form a hyperplastic restenotic
lesion.9 A variety of excipient carrier molecules have been
used to facilitate paclitaxel delivery to the target lesion,
including urea, iopromide, butyryl-tri-hexyl citrate, and
shellolic acid.10 During balloon inﬂation, these drugs are
liberated, some implanting as drug reservoirs into the
blood vessel wall to exert their effect locally, whereas other
clumps are released downstream in a phenomena known as
“particulate embolization.” This phenomenon was studied
by Heilmann et al11 in a porcine model, in which they
demonstrated that >50% of the drug coating washes off
into the distal circulation. In that study, the type of excip-
ient and method of balloon coating (drug-coated or wrap-
ped) affected the efﬁciency of drug transfer. In humanstudies, Freyhardt et al12 demonstrated paclitaxel within
the systemic circulation after lower limb DEB angioplasty.
There is concern about what long-term effect this shower
of drug into the end organ may have; however to date,
there have been no published reports of allergy or vasculitic
reactions. This has been reassuring for all who use these
devices and has resulted in their broad application to
include vascular territories where the end organ may be
less forgiving than the lower limb.10,13
We propose that our patient’s vasculitic rash was
related to particulate embolization of the drug coatings
on the balloon, of which paclitaxel and urea feature most
prominently. In support of this, we note that the rash
was present only in the vascular territory fed by the treated
superﬁcial femoral artery and appeared 5 days after that
treatment. Close physical examination of her skin and
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evidence of allergic or vasculitic reaction in other vascular
beds, conﬁrming that the process was isolated to her left
leg. It is likely that a reaction to the oral medications, intra-
venous sedatives, analgesics, and local anesthetics used in
the periprocedural period would have resulted in wider
evidence of a systemic reaction.
Theoretically, an inﬂammatory contaminant intro-
duced through the working sheath could have also caused
such a vasculitic reaction; however, no such contamination
occurred within the sterile operating theater environment
where the procedure took place. The patient did not
have allergies to docetaxel14 or hazelnuts,15 to which
cross-allergenicity to paclitaxel have been described.
Finally, atheroembolism was considered to have been
unlikely given that smooth in-stent restenosis was the
lesion targeted by angioplasty and the distal limb arteries
were patent when examined at the completion of the
procedure. Paclitaxel hypersensitivity rashes have been
previously described with variable features, at times similar
to the rash in this patient.16 Thus, we have a plausible
mechanism, a strong temporal relationship, and absence
of an alternative cause for her clinical syndrome.
To date, the published experience with DEBs has been
limited by small numbers and short follow-up. There are
no reports of end-organ or distal vascular bed lesions as
a result of deposition of the antiproliferative drug and
excipient. Stent hypersensitivities in the coronary literature
have been reported and investigated.17 Nebeker et al18
reviewed all drug-eluting stent hypersensitivities reported
to the Food and Drug Administration between 2003 and
2004, detecting stents in 17 patients that caused a hyper-
sensitivity reaction resulting in eosinophilic inﬂammation,
thrombosis, or lack of intimal healing. Explanted samples
demonstrated stent thrombosis and vascular ectasia due
to an eosinophilic inﬂammation that resulted in a lack of
intimal healing. Distal vascular bed lesions, such as the
one in our patient, have not been demonstrated.
Generational development of DEBs has seen evolving
improvements in target lesion drug delivery determined
largely by the carrier excipient molecule used. These carrier
molecules are critical in determining the volume of drugs
delivered to and retained within the target lesion, as well
as the proportion of drugs lost downstream.19 Newer-
generation DEBs promise to improve drug delivery and
vessel wall retention while reducing particulate emboliza-
tion. These excipient variations may avoid the distal
vascular injuries seen in this patient.
As a ﬁrst report of vasculitis from a DEB, this is an iso-
lated event by deﬁnition. However, in the context of a new
technology with little published experience, it may be
considered a warning to users at a time when there is
uncertainty about the incidence of the event, but many
are seeking to broaden the application of DEBs into new
vascular territories. Our patient is progressing toward
a full recovery; however, if this DEB had been used in
her carotid, renal, or mesenteric circulation, such a vasculitis
might have resulted in a major serious adverse event.CONCLUSIONS
We present here a patient with vasculitic rash of the
lower limb after treatment with a DEB, thought to be
a reaction to particulate embolization of paclitaxel and
urea. Although DEBs have been shown to improve patency
in the treatment of arterial occlusive disease, hypersensi-
tivity reactions with serious clinical consequences may
occur and warrant careful consideration.We acknowledge Dr Geoff O’Brien, of Healthscope
Pathology, for his assistance with the histopathologic
analysis.
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